Implications of Low-Titer MOG Antibodies
Mult Scler Relat Disord
.
2022 Mar:59:103746.
doi: 10.1016/j.msard.2022.103746.
Epub 2022 Mar 17.
Authors
Michael Levy
1
,
E Ann Yeh
2
,
Christopher H Hawkes
3
,
Jeannette Lechner-Scott
4
,
Gavin Giovannoni
5
Affiliations
1
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: MLEVY11@mgh.harvard.edu.
2
The Hospital for Sick Children, University of Toronto, Toronto, M5G 1 × 8, Ontario, Canada.
3
Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, UK.
4
John Hunter Hospital Department of Neurology, Newcastle, 2305, Australia.
5
Queen Mary University of London, Barts and the London School of Medicine and Dentistry, Centre for Neuroscience and Trauma, London, United Kingdom.
PMID:
35320765
DOI:
10.1016/j.msard.2022.103746
No abstract available
Keywords:
MOG; MOG antibody disease; MOGAD; low-titer.
Publication types
Editorial
MeSH terms
Aquaporin 4*
Autoantibodies*
Humans
Myelin-Oligodendrocyte Glycoprotein
Substances
Aquaporin 4
Autoantibodies
Myelin-Oligodendrocyte Glycoprotein